Thomson Reuters (TRI) Suspends Healthcare Business Sale; Cites Challenging Conditions
Tweet
Share
E-mailGet Alerts TRI Hot Sheet
Join SI Premium – FREE
Thomson Reuters (NYSE: TRI), has suspended the divestiture process for its Healthcare business.
Since announcing the planned divestiture in June, global economic conditions have become more challenging and the company believes they are not conducive to concluding a transaction that reflects the fair value of the Healthcare business at this time. Thomson Reuters is committed to continuing to invest in and grow the Healthcare business until improved market conditions allow the company to complete a divestiture at attractive terms.
The Healthcare business continues to perform well with strong revenue growth and expanding margins. The current organization and structure remain in place and the focus on serving customer needs is unchanged. The results of the Healthcare business will continue to be included within "Other Businesses" in Thomson Reuters financial statements.
Since announcing the planned divestiture in June, global economic conditions have become more challenging and the company believes they are not conducive to concluding a transaction that reflects the fair value of the Healthcare business at this time. Thomson Reuters is committed to continuing to invest in and grow the Healthcare business until improved market conditions allow the company to complete a divestiture at attractive terms.
The Healthcare business continues to perform well with strong revenue growth and expanding margins. The current organization and structure remain in place and the focus on serving customer needs is unchanged. The results of the Healthcare business will continue to be included within "Other Businesses" in Thomson Reuters financial statements.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Thomson Reuters Launches Next Generation of CoCounsel Legal, the AI Ecosystem Built for Legal Professionals
- Boeing names Ryan Shedd as new SVP and controller
- Cytek faces $56M damages award in Beckman Coulter patent case
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
